Login to access your membership accounts, education training and products and services.
As a regulatory professional, confidence comes from having the answers you need. But what do you do when the answers just aren't there? 2014 RAPS will give you the know-how to tackle your toughest issues.
Improve how effectively you network and advocate for yourself with ideas and techniques from this on-demand webcast.
Local or global—RAPS has you covered with offices in Washington, DC, Shanghai and Singapore. There are RAPS chapters in Canada, Israel, Switzerland, Taiwan and throughout the United States, and local networks in Australia, Belgium, Brazil, Germany, India, Mexico, The Netherlands, Poland and Singapore.
Placeholder for Higher Logic Forum Discussions - DO NOT DELETE
The results of the 2014 Scope of Practice & Compensation Report for the Regulatory Profession,
consistent with past surveys, show regulatory careers continue to offer
good pay, growth opportunities and challenging and diverse work.
Even if a person does not get what is deserved in life, a regulatory professional often has a better chance of getting what is deserved on the job if he or she can negotiate salary effectively. To evaluate worth to an employer, the regulatory professional must know him- or herself, the business ecosystem and his or her ability to deliver desired professional qualifications.
Could the US Food and Drug Administration (FDA) soon use Google to track drug-related adverse events?
Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.
Subscribe to RSS
Sign up for regular emails from RAPS. We'll never share your info and you can unsubscribe any time.
A new draft guidance document issued by the US Food and Drug Administration (FDA) is meant to eventually replace a 16-year-old guide outlining the regulator's views on informed consent. View More
US medical device regulators soon plan to hold a public hearing to discuss how the results of cardiovascular outcomes trials (CVOTs) can be kept confidential until they are completed. View More
The US Food and Drug Administration (FDA) has issued a rare Warning Letter chiding a company for, among other reasons, improperly "liking" certain unapproved claims about its product on Facebook. View More
Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. View More